OMRIX BIOPHARMACEUTICALS
The computed 12-month bankruptcy probability of OMRIX BIOPHARMACEUTICALS is 0.4% (very low). The company has been active since 1995 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 30 yrs |
| Locations | 1 |
| Publications | 14 |
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | volledig | 11-07-2025 | 2025-00267641 |
| 31-12-2023 | volledig | 05-07-2024 | 2024-00236558 |
| 31-12-2022 | volledig | 10-07-2023 | 2023-00220703 |
| 31-12-2021 | volledig | 27-06-2022 | 2022-20107626 |
| 31-12-2020 | volledig | 07-09-2021 | 2021-66800248 |
| 31-12-2019 | volledig | 09-07-2021 | 2021-34900588 |
| 31-12-2018 | volledig | 28-06-2019 | 2019-23900579 |
| 31-12-2017 | volledig | 02-07-2018 | 2018-26500418 |
| 31-12-2016 | volledig | 08-08-2017 | 2017-42300184 |
| 31-12-2015 | volledig | 22-08-2016 | 2016-47200184 |
| NACE primary | Wholesale trade(46460) |
| Legal form | Public limited company(014) |
| Incorporation | 31-08-1995 |
| Status | Active |
| Postal code | 1831 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates — not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23015B0291/02B000 | Flanders | 1.1 ha | 1 · 2,579 m² | 20.4 m · 6 fl. |
A single timeline of everything that happened to this company — publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
30-07-2024 2 directors appointed
- PWC Bedrijfsrevisoren BV — Commissaris
- Roel Boons — Vertegenwoordiger commissaris
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "PWC Bedrijfsrevisoren BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "vertegenwoordiger commissaris",
"person": {
"rrn": null,
"name": "Roel Boons",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}06-09-2023 1 director appointed, 2 resigning
- Elena GIRONI — Bestuurder
- Beverly PHARAOH — Bestuurder
- Sylvie BIANCHI — Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beverly PHARAOH",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sylvie BIANCHI",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Elena GIRONI",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}19-07-2023 1 director appointed, 1 resigning
- Sylvie BIANCHI — Bestuurder
- Beverly PHARAOH — Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beverly PHARAOH",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sylvie BIANCHI",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}22-07-2022 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}20-09-2021 Pricewaterhousecoopers BV appointed as statutory auditor
- Pricewaterhousecoopers BV — Commissaris
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Pricewaterhousecoopers BV",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}06-03-2020 8 directors appointed
- Hilde Claes — Lasthebber
- An de Schutter — Gemachtigde
- Heidi Moyson — Lasthebber
- Inge Gabriëls — Lasthebber
- Sophie Totté — Lasthebber
- Audrey Rottier — Lasthebber
- Eva Veraghtert — Lasthebber
- Leen Van De Wiel — Gemachtigde
Technical details
{
"events": [
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Hilde Claes",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Gemachtigde",
"person": {
"rrn": null,
"name": "An de Schutter",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Heidi Moyson",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Inge Gabri\u00EBls",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Sophie Tott\u00E9",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Audrey Rottier",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Eva Veraghtert",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Gemachtigde",
"person": {
"rrn": null,
"name": "Leen Van De Wiel",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}30-12-2019 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
},
"legal_form_change": {
"new": "naamloze vennootschap",
"old": "naamloze vennootschap",
"changed": false
}
}26-09-2019 1 director appointed, 1 resigning
- Peter D'hondt — Vertegenwoordiger van de commissaris
- Bart Van Gompel — Vertegenwoordiger van de commissaris
Technical details
{
"events": [
{
"kind": "director_out",
"role": "vertegenwoordiger van de commissaris",
"person": {
"rrn": null,
"name": "Bart Van Gompel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "vertegenwoordiger van de commissaris",
"person": {
"rrn": null,
"name": "Peter D\u0027hondt",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}18-07-2018 1 director appointed, 1 resigning
- PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA — Auditor
- PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA — Auditor
Technical details
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "auditor",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}11-07-2017 2 directors appointed, 1 resigning
- Wim Adriaenssens — Bestuurder
- Beverly Pharaoh — Bestuurder
- Raf Uyttenbroeck — Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Raf Uyttenbroeck",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Wim Adriaenssens",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beverly Pharaoh",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}24-09-2015 2 directors appointed
- PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA — Commissaris
- Bart Van Gompel — Bedrijfsrevisor
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bedrijfsrevisor",
"person": {
"rrn": null,
"name": "Bart Van Gompel",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}02-02-2011 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
},
"legal_form_change": {
"new": "naamloze vennootschap",
"old": "naamloze vennootschap",
"changed": false
}
}02-02-2011 Registered office moved from Bruxelles to Sint-Stevens-Woluwe
- 1180 Bruxelles, avenue Blücher 63 → 1932 Sint-Stevens-Woluwe, Lenneke Marelaan 6
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "1932 Sint-Stevens-Woluwe, Lenneke Marelaan 6",
"city": "Sint-Stevens-Woluwe",
"region": "vlaams_gewest",
"street": "Lenneke Marelaan",
"country": "BE",
"postcode": "1932",
"box_number": null,
"street_number": "6",
"locality_suffix": null
},
"old_address": {
"raw": "1180 Bruxelles, avenue Bl\u00FCcher 63",
"city": "Bruxelles",
"region": "brussels_hoofdstedelijk_gewest",
"street": "avenue Bl\u00FCcher",
"country": "BE",
"postcode": "1180",
"box_number": null,
"street_number": "63",
"locality_suffix": null
},
"effective_date": "2010-12-15",
"evidence_quote": "Transfert du si\u00E8ge social \u00E0 1932 Sint-Stevens-Woluwe, Lenneke Marelaan 6, et modification de l\u0027article 2 des statuts comme repris dans la nouvelle version n\u00E9erlandaise des statuts.",
"region_changed": true,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "header_volledig_adres",
"statute_clause_text": "Le si\u00E8ge social est transf\u00E9r\u00E9 \u00E0 1932 Sint-Stevens-Woluwe, Lenneke Marelaan 6.",
"statute_article_number": "2",
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": true,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "Denis DECKERS",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2011-02-02",
"filing_date": "2011-01-21",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"date": "2010-12-15",
"unanimous": true
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "B-DOCS",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"proc\u00E8s-verbal",
"deux procurations"
]
}30-10-2009 4 directors appointed
- Marci Blazer — Bestuurder
- Chery Foytlin — Bestuurder
- James J. Bergin — Bestuurder
- Elizabeth Forminard — Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marci Blazer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chery Foytlin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "James J. Bergin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Elizabeth Forminard",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | OMRIX BIOPHARMACEUTICALS |